

Supplementary Text 1. Features predicting future recurrence of SARS-CoV-2 nasopharyngeal swab PCR positivity

The leading features in the algorithm predicting recurrence of PCR positivity included: age; BMI; lowest levels of the blood laboratory tests during hospitalization for cholinesterase, fibrinogen, albumin, prealbumin, calcium, eGFR, creatinine; highest levels of the blood laboratory tests during hospitalization for total bilirubin, lactate dehydrogenase, and alkaline phosphatase; the first test results during hospitalization for partial pressure of oxygen, total white blood cell and lymphocyte counts, blood procalcitonin; and the first test result and lowest level of Ct value of the nasopharyngeal swab RT PCR results.

The model identified serum concentrations of cholinesterase, calcium, and eGFR as predictors, and the elevation of the three markers were associated the increasing risk of recurrence of PCR positivity. Previous studies found that cholinesterase, calcium, and eGFR were all associated with the severity of COVID-19. A study in Zunyi, China found that cholinesterase levels in mild COVID-19 cases were significantly higher than those in severe cases¹. Shanghai Public Health Clinical Centre found that among 198 COVID-19 patients, non-ICU patients had significantly higher levels of calcium than those who were admitted to ICU². A study on 701 patients in Tongji Hospital, China revealed that kidney disease was associated with in-hospital deaths of patients with COVID-19. Furthermore, eGFR, a marker of kidney dysfunction, was found significantly lower in severe patients with COVID-19³. All these findings suggested that increased levels of cholinesterase, calcium, and eGFR were associated with mild COVID-19. In our study, mild or moderate patients had more chance to get recurrence of PCR positivity. The associations of the blood markers and the recurrence of PCR positivity outcomes revealed by our model therefore were consistent with results from other centers.

1. Xiang J, Wen J, Yuan X, et al. Potential biochemical markers to identify severe cases among COVID-19 patients. *medRxiv*. 2020.
2. Cao M, Zhang D, Wang Y, et al. Clinical Features of Patients Infected with the 2019 Novel Coronavirus (COVID-19) in Shanghai, China. *medRxiv*. 2020.
3. Cheng Y, Luo R, Wang K, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. *Kidney Int*. 2020;97(5):829-838.